Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI
Therapeutic Advances in Respiratory Disease · Published 2025-11-01 · DOI 10.1177/17534666251393070
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/17534666251393070
Abstract
Background: Cystic fibrosis (CF) outcomes are influenced by a myriad of genetic, microbiological, and environmental factors, as well as socioeconomic constraints. Studies have shown that low socioeconomic status is associated with a higher risk of death, lower body weight and height, worsened pulmonary function, and increased pulmonary exacerbation in children with CF. Screening for social risk factors (SRFs) is one possible approach to help mitigate unmet social needs in people with CF (PwCF). Objectives: Does a positive screening response for SRF correlate with health outcomes in PwCF? Design: This is a single-center, retrospective analysis of outcomes in adult PwCF. The study includes data from 2021 to 2022. Methods: A social needs screening tool was administered to identify SRF in PwCF in eight domains: housing, food, transportation, utilities, healthcare cost, medication cost, income/employment, and education. A total of 121 PwCF were included in the analysis. Linear mixed-effects models, Poisson regression, and mixed-effects Cox regression were used for analyses of multivariate models. Results: When adjusted for multiple covariables, PwCF who screened positive for SRF had similar lung function and BMI as PwCF who reported no SRF and an increased CF exacerbation rates per person/per year when compared to their peers, 1.700 (1.275, 2.266) versus 0.829 (0.608, 1.130) ( p = 0.006). Adjusted models showed that the median time to exacerbation was significantly lower in PwCF who screened positive for SRF (210 days vs 389 days). Conclusion: PwCF who responded positively for SRF experienced an increased rate of CF exacerbation, and this finding remained significant when adjusted for multiple variables, including new CF medications. Medication cost, income/employment concerns, and food insecurity emerged as the most significant predictors of exacerbation rates and time to the next exacerbation. Further studies are needed to evaluate effective interventions and resources to mitigate SRF.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2025
Related articles
- Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of “aged” people with cystic fibrosis · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Spontaneous pneumothorax-associated with genetic disorders · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Effects of dual bronchodilation on right ventricular function and troponin-I in newly diagnosed, moderate-to-severe chronic obstructive pulmonary disease: a prospective real-world observational study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Tislelizumab in conjunction with chemotherapy for the treatment of nasal metastasis from lung squamous cell carcinoma: a case report and literature review · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Pulmonary tuberculosis during the developmental period contributes to COPD and pre-COPD in mid-to-late adulthood: a retrospective cohort study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The association between mental health, cognitive functioning, and health-related quality of life in adults with chronic nontuberculous mycobacterial pulmonary disease · Therapeutic Advances in Respiratory Disease · 2025 · Same journal